Actively Recruiting
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Led by Sun Yat-sen University · Updated on 2025-11-17
168
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
This study aims to explore the safety and efficacy of eliminating the planning target volume (PTV) margins based on MRI-guided adaptive stereotactic radiotherapy for non-small cell lung cancer (NSCLC) patients with brain metastasis.
CONDITIONS
Official Title
Elimination of PTV Margins Based on MRI-guided Adaptive Stereotactic Radiotherapy for Non-small Cell Lung Cancer With Brain Metastasis
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Aged 18-75 years
- Histologically or cytologically confirmed non-small cell lung cancer
- 1-10 brain metastases visible on contrast-enhanced MRI
- Radiotherapy for extracranial lesions is allowed
- Use of tyrosine kinase inhibitors permitted if intracranial metastases progressed during prior therapy
- Measurable or evaluable lesions by RECIST criteria
- ECOG performance status of 0 or 1
- Normal organ and bone marrow function within 14 days: total bilirubin ≤1.5 times upper limit normal (ULN); AST and ALT ≤1.5 times ULN; absolute neutrophil count ≥500 cells/mm3; creatinine clearance ≥45 mL/min; platelet count ≥50,000 cells/mm3; INR ≤1.5; prothrombin time ≤1.5 × ULN
- Provided informed consent
You will not qualify if you...
- Small cell lung carcinoma
- Brain metastases requiring surgical decompression
- Contraindications to MRI
- Previous radiotherapy or surgical removal of brain metastases
- Hypertensive crisis, hypertensive encephalopathy, symptomatic heart failure (NYHA class II or above), or recent cerebrovascular or cardiovascular events within 6 months
- Uncontrolled high blood pressure (systolic >150 mmHg or diastolic >100 mmHg)
- Major surgery within 28 days or minor surgery/needle biopsy within 48 hours
- Significant protein in urine (3-4+), or 24-hour urine protein >1 g
- Severe uncontrolled diseases
- Uncontrollable seizures or psychosis without self-control
- Pregnancy or breastfeeding
- Other conditions deemed unsuitable by investigators
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Sun yat-sen University Cancer Center
Guangzhou, Guangdong, China, 510060
Actively Recruiting
Research Team
H
Hui Liu
CONTACT
D
DaQuan Wang
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here